Amide-sulfamide modulators as effective anti-tumor metastatic agents targeting CXCR4/CXCL12 axis

被引:11
|
作者
Wu, Rui [1 ]
Yu, Wenyan [1 ]
Yao, Chuansheng [1 ]
Liang, Zhongxing [2 ]
Yoon, Younghyoun [2 ]
Xie, Yuanyuan [1 ]
Shim, Hyunsuk [2 ,3 ]
Bai, Renren [1 ]
机构
[1] Zhejiang Univ Technol, Coll Pharmaceut Sci, 18 Chaowang Rd, Hangzhou 310014, Zhejiang, Peoples R China
[2] Emory Univ, Sch Med, Dept Radiat Oncol, 1701 Uppergate Dr,C5018, Atlanta, GA 30322 USA
[3] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
基金
中国国家自然科学基金;
关键词
CXCR4/CXCL12; axis; Amide-sulfamide derivatives; Structural modification; Anti-tumor metastatic activity; CXCR4; POTENT; AMINES; ANTAGONISTS; CXCL12; DESIGN;
D O I
10.1016/j.ejmech.2019.111823
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Breast cancer is the most frequently diagnosed malignancy and the second common cause of death in women worldwide. High mortality in breast cancer is frequently associated with metastatic progression rather than the primary tumor itself. It has been recently identified that the CXCR4/CXCL12 axis plays a pivotal role in breast cancer metastasis, especially in directing metastatic cancer cells to CXCL12-riched organs and tissues. Herein, taking the amide-sulfamide as the lead structure, the second-round structural modifications to the sulfamide structure were performed to obtain more active CXCR4 modulators against tumor metastasis. Both in vivo and in vitro experiments illustrated that compound he possessed potent CXCR4 binding affinity, excellent anti-metastatic and anti-angiogenetic activity against breast cancer. More importantly, in a mouse breast cancer lung metastasis model, compound Me exerted a significant inhibitory effect on breast cancer metastasis. Taken together, all these positive results demonstrated that developing of CXCR4 modulators is a promising strategy to mediate breast cancer metastasis. (C) 2019 Elsevier Masson SAS. All rights reserved.
引用
收藏
页数:13
相关论文
共 50 条
  • [11] A review on CXCR4/CXCL12 axis in oncology: No place to hide
    Domanska, Urszula M.
    Kruizinga, Roeliene C.
    Nagengast, Wouter B.
    Timmer-Bosscha, Hetty
    Huls, Gerwin
    de Vries, Elisabeth G. E.
    Walenkamp, Annemiek M. E.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (01) : 219 - 230
  • [12] Targeting the CXCR4/CXCL12 axis with the peptide antagonist E5 to inhibit breast tumor progression
    Guo, Hua
    Ge, Yangyang
    Li, Xiaojin
    Yang, Yanlian
    Meng, Jie
    Liu, Jian
    Wang, Chen
    Xu, Haiyan
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2017, 2
  • [13] CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression
    Sun, Xueqing
    Cheng, Guangcun
    Hao, Mingang
    Zheng, Jianghua
    Zhou, Xiaoming
    Zhang, Jian
    Taichman, Russell S.
    Pienta, Kenneth J.
    Wang, Jianhua
    CANCER AND METASTASIS REVIEWS, 2010, 29 (04) : 709 - 722
  • [14] CXCR4/CXCL12 axis: "old" pathway as "novel" target for anti-inflammatory drug discovery
    Lu, Liuxin
    Li, Junjie
    Jiang, Xiaoying
    Bai, Renren
    MEDICINAL RESEARCH REVIEWS, 2024, 44 (03) : 1189 - 1220
  • [15] Mechanisms by which CXCR4/CXCL12 cause metastatic behavior in pancreatic cancer
    Zhang, Jianbo
    Liu, Chengxin
    Mo, Xinkai
    Shi, Huan
    Li, Sheng
    ONCOLOGY LETTERS, 2018, 15 (02) : 1771 - 1776
  • [16] CXCR4/CXCL12 Activities in the Tumor Microenvironment and Implications for Tumor Immunotherapy
    Mezzapelle, Rosanna
    Leo, Manuela
    Caprioglio, Francesca
    Colley, Liam S.
    Lamarca, Andrea
    Sabatino, Lina
    Colantuoni, Vittorio
    Crippa, Massimo P.
    Bianchi, Marco E.
    CANCERS, 2022, 14 (09)
  • [17] The CXCL12/CXCR4 chemokine ligand/receptor axis in cardiovascular disease
    Doering, Yvonne
    Pawig, Lukas
    Weber, Christian
    Noels, Heidi
    FRONTIERS IN PHYSIOLOGY, 2014, 5
  • [18] Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia
    Ladikou, Eleni E.
    Chevassut, Timothy
    Pepper, Chris J.
    Pepper, Andrea G. S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (05) : 815 - 825
  • [19] Exploring the CXCR4/CXCR7/CXCL12 Axis in Primary Desmoid Tumors
    Baccalini, Edoardo Andrea
    Renne, Salvatore Lorenzo
    Colombo, Piergiuseppe
    Pasqualini, Fabio
    Quagliuolo, Vittorio Lorenzo
    Cananzi, Ferdinando Carlo Maria
    Grizzi, Fabio
    Borroni, Elena Monica
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2023, 23 (20) : 2248 - 2253
  • [20] Potential of CXCR4/CXCL12 Chemokine Axis in Cancer Drug Delivery
    Wang Y.
    Xie Y.
    Oupický D.
    Current Pharmacology Reports, 2016, 2 (1) : 1 - 10